Drug Profile
Exebacase - ContraFect
Alternative Names: CF-301; Lysin CF-301Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Rockefeller University
- Developer ContraFect
- Class Antibacterials; Endolysins; Enzymes; Recombinant proteins
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Bacteraemia
- Phase I/II Staphylococcal infections
- No development reported Infections; Osteomyelitis; Skin and soft tissue infections
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Osteomyelitis in USA (IV)
- 20 Apr 2023 Antimicrobial data from a preclinical in Staphylococcal infections released by ContraFect
- 03 Apr 2023 Phase-I/II clinical trials in Staphylococcal infections in France (Intra-articular)